Apricus Biosciences Inc (APRI) Stock Price & Overview
NASDAQ:APRI
Current stock price
The current stock price of APRI is 0.22 null. Today APRI is down by -4.35%. In the past month the price increased by 15.79%. In the past year, price decreased by -90.52%.
APRI Key Statistics
- Market Cap
- 6.197M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.52
- Dividend Yield
- N/A
APRI Stock Performance
APRI Stock Chart
APRI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APRI. When comparing the yearly performance of all stocks, APRI is a bad performer in the overall market: 98.39% of all stocks are doing better.
APRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APRI. APRI has a bad profitability rating. Also its financial health evaluation is rather negative.
APRI Earnings
APRI Forecast & Estimates
APRI Financial Highlights
Over the last trailing twelve months APRI reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 13.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.71% | ||
| ROE | -239.05% | ||
| Debt/Equity | 0 |
APRI Ownership
About APRI
Company Profile
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
Company Info
Apricus Biosciences Inc
11975 EL CAMINO REAL SUITE 300
SAN DIEGO CA 92130
CEO: Richard W. Pascoe
Phone: 858-222-8041
Apricus Biosciences Inc / APRI FAQ
What does Apricus Biosciences Inc do?
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
What is the current price of APRI stock?
The current stock price of APRI is 0.22 null. The price decreased by -4.35% in the last trading session.
What is the dividend status of Apricus Biosciences Inc?
APRI does not pay a dividend.
What is the ChartMill rating of Apricus Biosciences Inc stock?
APRI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for APRI stock?
Apricus Biosciences Inc (APRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).